Navigation Links
PneumRx, Inc. Raises $33 Million in Capital
Date:1/4/2011

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has raised $33 million in working capital commitments.  The oversubscribed round was led by Forbion Capital Partners and co-led by Endeavour Vision, both leading venture capital firms from Europe, and also included a prominent strategic corporate partner.  The syndicate was joined by existing investors Adams Street Partners, Telegraph Hill Partners, Alta Partners, and Spray Venture Partners, among others.  Silicon Valley Bank and Leader Ventures also contributed to the capital raise in PneumRx.

PneumRx recently established a subsidiary in Germany, PneumRx GmbH, and has begun selling its innovative RePneu Lung Volume Reduction Coil (LVRC) System in Europe. It plans to use the funds to expand European commercialization and to conduct an FDA-approved pivotal clinical trial to support a PMA application.  PneumRx expects to begin its pivotal clinical trial in early 2011 and intends to submit its pivotal trial results to support a PMA application to be able to sell the RePneu LVRC System in the United States.

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the lung.  This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.  More than 1500 LVR Coils have been implanted to date in over 170 procedures.  The LVRC System is CE Marked and is currently available in select markets in Europe, with plans for broader expansion.

"We are thrilled to have completed our Series C round and are pleased to add a top-tier med-tech corporate partner in this later financing round.  We believe that this partnership will be extremely beneficial as PneumRx prepares for its future pivotal trial, commercialization and reimbursement efforts in the US.  We also appreciate the addition of two prominent European venture firms to our board.  We look forward to working more closely with Forbion and Endeavour Vision as we expand our commercial efforts in Europe," said Erin McGurk, Founder, President and CEO of PneumRx, Inc.  "2010 was an exciting year for PneumRx, receiving our CE Mark and achieving our first European sales and we look forward to expanding into the US in 2011, with our plans for our pivotal clinical trial.  We are pleased to be able to bring our RePneu Lung Volume Reduction Coil treatment to a greater number of emphysema patients suffering from this debilitating disease."

Martien van Osch, Managing Partner at Forbion Capital Partners said, "PneumRx brings an effective therapy for a large group of emphysema patients. For most of these patients there are, to date, no good treatment alternatives.  Over 1500 coils have been implanted to date and the safety and efficacy profile is very exciting. We are proud to lead this current financing round and to help the company establish a presence and commercial infrastructure in Europe."

Daniel Bertholet, Investment Director at Endeavour Vision, commented, "Having reviewed all the companies in this sector, I am convinced that PneumRx has developed the most promising Lung Volume Reduction device to treat emphysema patients and is likely to become the preferred clinical option in a few years.  We are delighted to join the company in order to support both the European market launch and the pivotal clinical study."

Martien van Osch and Daniel Bertholet will both join the Board of Directors.

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.  For more information, please visit www.pneumrx.com.

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. For more information, please visit www.forbion.com.

About Endeavour Vision

Endeavour Vision, located in Geneva, Switzerland, is a venture capital investment firm which globally invests in both the Life Sciences and Information/Communication Technology sectors.  For more information, please visit www.endeavourvision.com.


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
2. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
3. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
4. CardioGenics Raises $1.9 Million in Private Placement
5. Perrigo Reports Record Earnings and Raises Full Year Adjusted EPS Guidance
6. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
7. immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
8. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
9. StatRad Raises the Bar With Fully Integrated Teleradiology Solution
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):